Robert E Hoffman currently serves as Chief Financial Officer at CytoDyn since May 2025 and holds board member positions at Esperion, TuHURA Biosciences, and FibroBiologics. Previously, Robert was the President and Chief Executive Officer of Kintara Therapeutics from November 2021 to October 2024 and Chairman of the Board at Kintara Therapeutics prior to this role. Robert also served on the boards of ASLAN Pharmaceuticals, Antibe Therapeutics Inc., and Kura Oncology, among others. Robert's experience is centered on translating novel science into life-saving medicines and advancing a pipeline of precision medicines. Educationally, Robert holds a degree from St. Bonaventure University, completed between 1984 and 1988.
This person is not in any teams
This person is not in any offices